June 1968
Volume 7, Issue 3
Free
Articles  |   June 1968
Effect of Ouabain on Aqueous Humor Formation Rate in Cats
Author Affiliations
  • W. W. OPPELT
    Department of Pharmacology and Therapeutics, University of Florida, College of Medicine Gainesville, Fla. 32601
  • E. D. WHITE, Jr.
    Department of Pharmacology and Therapeutics, University of Florida, College of Medicine Gainesville, Fla. 32601
Investigative Ophthalmology & Visual Science June 1968, Vol.7, 328-333. doi:
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      W. W. OPPELT, E. D. WHITE; Effect of Ouabain on Aqueous Humor Formation Rate in Cats. Invest. Ophthalmol. Vis. Sci. 1968;7(3):328-333.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

The effect of intravenous and intracameral ouabain on aqueous humor (AH) formation rates was measured in cats. AH formation rate was determined with continuous, posteroanterior chamber perfusion with an AH-like buffer containing trace quantities of inulin-C14. After intravenous injection of 67 µg of ouabain per kilogram, there was a 40 per cent reduction in AH formation rate, while 34 µg per kilogram caused a 26 per cent reduction. There was no change after 10 µg of intravenous ouabain per kilogram. In other experiments, ouabain-containing buffer was substituted for the control buffer after a control period. No change in AH formation rates was noted after intracameral perfusion with 10-4M, 10-6M, or 10-8M ouabain. It is concluded that high doses of intravenous ouabain significantly decrease AH formation rates, probably by inhibition of ciliary body Na-K activated adenosine triphosphatase. There is no effect on AH formation rates by high and low doses of intracameral ouabain.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×